共查询到20条相似文献,搜索用时 156 毫秒
1.
化疗是癌症综合治疗的重要手段之一,临床应用非常广泛(多为静脉给药),随着新的有效的抗癌药物的不断出现,对于用药的浓度,速度、剂量、时间的要求也越来越高,有些药物(如氟尿嘧啶)需长时间、高浓度静脉缓滴,一次治疗量需要48~120h持续滴入,如果采用传统的输液方法,将会给患者的 相似文献
2.
一位澳大利亚科学家发明了一种染料测试方法,能在数日内检测出化疗是否在杀死患者的癌细胞,从而使医生能早日制定其他不像化疗那样使人虚弱的治疗方案。[第一段] 相似文献
3.
微泵化疗的使用对延长患者的生命、提高生活质量有肯定的效果,我们对本科1997年~2006年12月份使用化疗泵进行化疗的患者护理经验进行总结,现将微泵使用过程中的护理经验和体会报告如下。 相似文献
4.
腹腔化疗在卵巢癌系统化疗中的应用 总被引:1,自引:0,他引:1
卵巢癌是女性生殖系统三大恶性肿瘤之一,至今缺乏有效的早期诊断方法,当患者自己发觉再就医,恶性肿瘤已非早期。目前治疗仍以卵巢癌肿瘤细胞减灭术及术前术后多疗程化疗为基本原则,药物以紫杉醇、铂类药物联合化疗最为推广。常规系统多疗程化疗多采用全身静脉化疗,本组病例采用 相似文献
5.
化疗是恶性肿瘤综合治疗的重要手段之一.静脉注射化疗药物是主要的给药途径,但化疗药物对血管组织损伤较大.在化疗过程中保护好静脉和局部组织,是确保化疗顺利进行的重要因素.因此我们应高度重视静脉化疗患者的血管保护. 相似文献
6.
7.
目的:评价胃癌介入化疗与全身化疗的疗效。方法:对60例经病理证实的胃癌患者进行回顾性分析,其中术前经介入插管化疗32例,全身性化疗28例,所用药物为氟尿嘧啶脱氧核苷(FuDR)、阿霉素等。结果:介入插管化疗组总有效率81.25%。全身性化疗组总有效率50.00%。结论:中晚期胃癌介入化疗疗效优于全身化疗。 相似文献
8.
胃癌是消化道最常见的恶性肿瘤,手术是治疗胃癌目前惟一有效且有可能治愈早期胃癌的方法。但由于受诊断水平的限制,目前临床收治的大部分是进展期胃癌,单纯手术治疗无法取得良好的预后效果。因此手术后的辅助化疗成为进展期胃癌综合治疗的重要组成部分,下面就胃癌化疗现状和个 相似文献
9.
10.
11.
D O White 《The Medical journal of Australia》1984,140(12):715-720
Progress in antiviral chemotherapy has taken place as a logical strategy for the design of antiviral agents has emerged. The second-generation nucleoside analogues, led by acyclovir, have proved their worth against herpesviruses and should now become a standard part of medical practice. Meanwhile, recombinant DNA technology has lowered the cost of interferons to the point at which the several human subtypes of these naturally occurring hormones can be subjected individually to controlled clinical trials against the viral diseases in the treatment of which they show promise. Yet, optimism about the future of antiviral chemotherapy must be tempered by the observation that most of the agents discussed in this review are described more accurately as promising rather than proven, and several of these have not yet been released in Australia at the time of writing. 相似文献
12.
13.
14.
15.
16.
17.
18.
19.
Beinert T Masuhr F Mwela E Schweigert M Flath B Harder H Binder D Oehm C Behse F Possinger K 《European journal of medical research》2000,5(10):415-423
Neuropathy is a dose-limiting side effect for a number of effective chemotherapeutic agents. A better understanding of effective mechanisms will lead to novel treatment strategies that will protect neurons without decreasing therapeutic efficacy. The assessment of the efficacy and neurotoxicity of various chemotherapeutic agents is vital, for a determination of the maximum allowable dose. The introduction of chemotherapy in the 50s and 60s of the twentieth century has resulted in the development of curative therapeutic interventions for patients with several types of solid tumours and hemopoietic neoplasms. The important obstacles encountered in the use of chemotherapy have been the toxicity to the normal tissue. During the past 8 years there has come about a new level of understanding of the mechanisms through which chemotherapeutic agents work. This has opened the door to new paradigms of treatment in which molecular, genetic, and biologic therapy can be used together to increase the sensitivity of abnormal cells to treatment, and to protect the normal tissues of the body from therapy-induced side effects. The implementation of new strategies could change the way therapy is delivered over the next few years and improve the outcome especially in patients with neoplasms that are currently resistant to conventional dose therapy. 相似文献
20.
目的 系统分析奥沙利铂治疗进展期胃癌的疗效和安全性以及应用前景.方法 通过检索中国数字化期刊全文数据库(CNKI)、万方数据库、维普全文网、美国国家医学图书馆查询系统(PubMed)中近6年来国内外公开发表的文献,收集以奥沙利铂为主的联合方案(试验组)对照顺铂联合方案(对照组)治疗进展期胃癌的临床试验数据,联合药物限定为氟尿嘧啶类(包括卡培他滨)和(或)表阿霉素.使用Review Manager4.2进行有效率、1年生存率、不良反应等方面的荟萃分析.结果 共16篇文献入选,总计2121例胃癌患者,其中试验组1062例,对照组1059例.奥沙利铂为主的联合方案组的有效率(46.3%)较顺铂组(40.6%)高(OR:1.28,P:0.006),1年生存率也高(44.6%比39.3%,OR=1.25,P=0.04);而不良反应中试验组的周围神经毒性的发生率高于对照组(70.6%比21.9%,OR:10.76,P<0.01),贫血(58.0%比70.1%,OR=1.65)和恶心呕吐(61.4%比75.6%,OR=1.32)的发生率则低,差异均有统计学意义(均P<0.05).结论 与既往的顺铂为主的方案相比,奥沙利铂为主的化疗方案在治疗进展期胃癌方面有更好的疗效,相对较安全,患者更易耐受. 相似文献